Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Clinical trial NCT05996263 · UNKNOWN
Trial details
- NCT number
- NCT05996263
- Sponsor
- University Hospital, Brest
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2023-08-01
- Primary completion
- 2023-08-31
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.